CoChat

Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?

Open access
Chaki, Shigeyuki · 2018 · International Journal of Neuropsychopharmacology
Cited by 17

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Major depressive disorder (MDD) affects approximately 10% to 20% of the US population (Kessler et al., 2005); thus, the economic burden of MDD is immense. Currently, selective serotonin reuptake inhibitors and serotonin- and noradrenaline-reuptake inhibitors are widely prescribed for patients with MDD as first-line treatments. However, these medications have several drawbacks; approximately 30% of patients remain inadequately treated even after a series of treatments and it takes several weeks for these medications to manifest their antidepressant actions (Rush et al., 2006; Trivedi et al., 2006). New treatment options with mechanisms of action distinct from current medications are long awaited. Ketamine, a drug used as a dissociative anesthetic, shed light on this long-desired requirement. A subanesthetic dose of ketamine has been reported to exert rapid (<2 h) and long-lasting (>1 week) antidepressant effects in not only patients with MDD but also those with treatment-resistant depression (Berman et al., 2000; Zarate et al., 2006). Furthermore, ketamine rapidly reduced suicidal ideation in depressed patients (Price et al., 2015; Ionescu et al., 2016). These ground-breaking findings could change depression therapy. However, ketamine elicits side effects such as psychotomimetic/dissociative symptoms right after injection, and abuse potential and neurotoxocity on long-term treatment. All these shortcomings prevent ketamine from routine use in daily practice. To develop agents having ketamine-like antidepressant effects but fewer side effects, enormous efforts have recently been made to understand mechanisms underlying antidepressant actions of ketamine. Indeed, these efforts have helped elucidate the role of AMPA receptor stimulation and subsequent activation of brain-derived neurotrophic factor signaling and synaptogenesis, which may be triggered by N-methyl-D-aspartate (NMDA) receptor blockade (Li et al., 2010; Krystal et al., 2013; Koike and Chaki, 2014) in the actions of ketamine, and additional mechanisms have also been being proposed (Belujon and Grace, 2014; Carreno et al., 2016). Still, an important issue remains to fully understand the mechanisms of ketamine. Which substance(s) produced in the body following ketamine administration is responsible for the antidepressant effects? Ketamine is a racemic mixture of (S)- and (R)-enantiomers. It is well known that ketamine is rapidly and stereoselectively metabolized by multiple hepatic cytochrome P450 (CYP) enzyme isoforms to a broad array of metabolites, including the norketamine, 2 diastereomeric hydroxyketamines, a series of 6 diastereomeric hydroxynorketamine (HNK), and dehydronorketamine (for review, see Chaki, 2017). Recently, 2 important findings were reported on active substances of ketamine. First, although (S)-ketamine has long been believed as an active substance for the actions of ketamine, (R)-ketamine has been reported to exhibit longer-lasting and more potent antidepressant effects than (S)-ketamine in animal models (Zhang et al., 2014; Yang et al., 2015; Fukumoto et al., 2017). Moreover, (R)-ketamine does not induce unwanted side effects such as abuse potential and neurotoxicity in rodents, observed with ketamine treatment (Yang et al., 2015). More importantly, Zanos et al. (2016) have reported that not only has (R)-ketamine more potent antidepressant effects than (S)-ketamine, but also the metabolism of ketamine to (2S,6S;2R,6R)-HNK is essential and sufficient to exert the antidepressant effects of ketamine. In their studies, they demonstrated that ketamine deuterated at the C6 position (6,6-dideuteroketamine) to prevent metabolism by CYP enzymes no longer exhibited antidepressant action at 24 h after administration in the mouse forced swimming test and learned helplessness model. Furthermore, they claimed that (2R,6R)-HNK plays a critical role in the antidepressant effects of ketamine because (2R,6R)-HNK demonstrated much more potent antidepressant effects than (2S,6S)-HNK. Based on these results, (2R,6R)-HNK is suggested to be the active substance produced in the body following ketamine administration and responsible for the antidepressant effects of ketamine (also (R)-ketamine). In addition, (2R,6R)-HNK was devoid of unwanted side effects ketamine exhibited in rodents. These findings raise the possibility that (2R,6R)-HNK could be a ketamine-like antidepressant with fewer side effects, as well as the need to reconsider the mechanisms of ketamine, which are based on NMDA receptor inhibition, since (2R,6R)-HNK has very weak activity at the NMDA receptor. However, there are some contradictory findings. Although (2R,6R)-HNK is derived solely by metabolism of (R)-ketamine, (S)-ketamine did exhibit antidepressant effects in either rodents (du Jardin et al., 2016; Ardalan et al., 2017) or depressed patients (Singh et al., 2016). Consequently, the antidepressant actions of ketamine cannot be explained solely by (2R,6R)-HNK. Furthermore, Hashim

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyx120

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 18

  1. Ardalan, 2017, S-ketamine rapidly reverses synaptic and vascular deficits of hippocampus in genetic animal model of depression, Int J Neuropsychopharmacol, 20, 247
  2. Berman, 2000, Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9 · DOI · Paper page
  3. Chaki, 2017, Beyond ketamine: new approaches to the development of safer antidepressants, Curr Neuropharmacol, 15, 963, 10.2174/1570159X15666170221101054 · DOI · Paper page
  4. du Jardin, 2016, Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression, Psychopharmacology (Berl), 233, 2813, 10.1007/s00213-016-4327-5 · DOI
  5. Kessler, 2005, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication, Arch Gen Psychiatry, 62, 617, 10.1001/archpsyc.62.6.617 · DOI · Paper page
  6. Koike, 2014, Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats, Behav Brain Res, 271, 111, 10.1016/j.bbr.2014.05.065 · DOI
  7. Krystal, 2013, Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond, Biol Psychiatry, 73, 1133, 10.1016/j.biopsych.2013.03.026 · DOI · Paper page
  8. Li, 2010, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Science, 329, 959, 10.1126/science.1190287 · DOI · Paper page
  9. Price, 2015, Does ketamine have anti-suicidal properties? Current status and future directions, CNS Drugs, 29, 181, 10.1007/s40263-015-0232-4 · DOI · Paper page
  10. Sałat, 2015, Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor, Neuropharmacology, 99, 301, 10.1016/j.neuropharm.2015.07.037 · DOI · Paper page
  11. Shirayama, 2002, Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression, J Neurosci, 22, 3251, 10.1523/JNEUROSCI.22-08-03251.2002 · DOI · Paper page
  12. Shirayama, 2017, Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression, Eur Arch Psychiatry Clin Neurosci, 267, 177, 10.1007/s00406-016-0718-1 · DOI
  13. Shirayama, 2018, Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine, Int J Neuropsychopharmacol, 21, 84, 10.1093/ijnp/pyx108 · DOI · Paper page
  14. Singh, 2016, Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study, Biol Psychiatry, 80, 424, 10.1016/j.biopsych.2015.10.018 · DOI · Paper page
  15. Trivedi, 2006, STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice, Am J Psychiatry, 163, 28, 10.1176/appi.ajp.163.1.28 · DOI · Paper page
  16. Yang, 2017, R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine, Biol Psychiatry, 82, e43, 10.1016/j.biopsych.2016.12.020 · DOI · Paper page
  17. Zarate, 2006, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Arch Gen Psychiatry, 63, 856, 10.1001/archpsyc.63.8.856 · DOI · Paper page
  18. Zhang, 2014, R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine, Pharmacol Biochem Behav, 116, 137, 10.1016/j.pbb.2013.11.033 · DOI · Paper page

Cited by

See all 17

Metadata

Authors
Chaki, S.
Venue
International Journal of Neuropsychopharmacology
Published
2017-12-26
Volume
21
Issue
2
Pages
154-156
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2779471433
Cited by
17
References
8
FWCI
1.96
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects? https://app.cochat.ai/papers/10.1093/ijnp/pyx120
The paper
Chaki, S. (2018). Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects? International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyx120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.